Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma

Haematologica. 2008 Mar;93(3):471-2. doi: 10.3324/haematol.12013.

Abstract

Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been successfully evaluated in the management of non-Hodgkin's lymphoma (NHL).1-3 Histological transformation (HT) of indolent lymphoma is a dramatic event that occurs in 5-10% of the patients and carries a dismal prognosis.4,5 Previous studies prove that indolent lymphoma entities show a lower FDG uptake when compared with aggressive lymphomas.6-8 We therefore postulated that FDG-PET/CT identifies aggressive transformation sites and can guide biopsies.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood
  • Biopsy / methods*
  • Disease Progression
  • Female
  • Fluorine Radioisotopes* / pharmacokinetics
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Lymphoma, Non-Hodgkin / blood
  • Lymphoma, Non-Hodgkin / diagnostic imaging*
  • Lymphoma, Non-Hodgkin / pathology
  • Male
  • Middle Aged
  • Positron-Emission Tomography*
  • Prospective Studies
  • Radiology, Interventional / methods*
  • Radiopharmaceuticals* / pharmacokinetics
  • Tomography, X-Ray Computed / methods*

Substances

  • Biomarkers, Tumor
  • Fluorine Radioisotopes
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18